Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 1.48
SNPHY's Cash to Debt is ranked higher than
70% of the 1152 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.37 vs. SNPHY: 1.48 )
SNPHY' s 10-Year Cash to Debt Range
Min: 1.48   Max: No Debt
Current: 1.48

Equity to Asset 0.70
SNPHY's Equity to Asset is ranked higher than
79% of the 1034 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.58 vs. SNPHY: 0.70 )
SNPHY' s 10-Year Equity to Asset Range
Min: 0.7   Max: 0.87
Current: 0.7

0.7
0.87
F-Score: 4
Z-Score: 3.11
WACC vs ROIC
7.66%
13.33%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 17.96
SNPHY's Operating margin (%) is ranked higher than
88% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 9.84 vs. SNPHY: 17.96 )
SNPHY' s 10-Year Operating margin (%) Range
Min: 15.25   Max: 27.74
Current: 17.96

15.25
27.74
Net-margin (%) 11.45
SNPHY's Net-margin (%) is ranked higher than
83% of the 1102 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.10 vs. SNPHY: 11.45 )
SNPHY' s 10-Year Net-margin (%) Range
Min: 9.96   Max: 19.25
Current: 11.45

9.96
19.25
ROE (%) 9.70
SNPHY's ROE (%) is ranked higher than
77% of the 1129 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.93 vs. SNPHY: 9.70 )
SNPHY' s 10-Year ROE (%) Range
Min: 8.02   Max: 14.51
Current: 9.7

8.02
14.51
ROA (%) 7.19
SNPHY's ROA (%) is ranked higher than
82% of the 1161 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.32 vs. SNPHY: 7.19 )
SNPHY' s 10-Year ROA (%) Range
Min: 6.58   Max: 12.13
Current: 7.19

6.58
12.13
ROC (Joel Greenblatt) (%) 37.47
SNPHY's ROC (Joel Greenblatt) (%) is ranked higher than
89% of the 1156 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 15.14 vs. SNPHY: 37.47 )
SNPHY' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: 37.82   Max: 53.64
Current: 37.47

37.82
53.64
Revenue Growth (3Y)(%) 11.60
SNPHY's Revenue Growth (3Y)(%) is ranked higher than
80% of the 932 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. SNPHY: 11.60 )
SNPHY' s 10-Year Revenue Growth (3Y)(%) Range
Min: 2.8   Max: 11.6
Current: 11.6

2.8
11.6
EBITDA Growth (3Y)(%) -1.60
SNPHY's EBITDA Growth (3Y)(%) is ranked higher than
67% of the 839 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.70 vs. SNPHY: -1.60 )
SNPHY' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -4.2   Max: 14.3
Current: -1.6

-4.2
14.3
EPS Growth (3Y)(%) -6.00
SNPHY's EPS Growth (3Y)(%) is ranked higher than
66% of the 811 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.80 vs. SNPHY: -6.00 )
SNPHY' s 10-Year EPS Growth (3Y)(%) Range
Min: -6   Max: 19.5
Current: -6

-6
19.5
» SNPHY's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with SNPHY

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 36.70
SNPHY's P/E(ttm) is ranked higher than
79% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 64.60 vs. SNPHY: 36.70 )
SNPHY' s 10-Year P/E(ttm) Range
Min: 11.02   Max: 40.47
Current: 36.7

11.02
40.47
PE(NRI) 36.60
SNPHY's PE(NRI) is ranked higher than
82% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 61.40 vs. SNPHY: 36.60 )
SNPHY' s 10-Year PE(NRI) Range
Min: 11   Max: 40.44
Current: 36.6

11
40.44
P/B 0.70
SNPHY's P/B is ranked higher than
96% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.13 vs. SNPHY: 0.70 )
SNPHY' s 10-Year P/B Range
Min: 0.3   Max: 1.94
Current: 0.7

0.3
1.94
P/S 4.20
SNPHY's P/S is ranked higher than
57% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 4.19 vs. SNPHY: 4.20 )
SNPHY' s 10-Year P/S Range
Min: 0.73   Max: 4.63
Current: 4.2

0.73
4.63
POCF 28.10
SNPHY's POCF is ranked higher than
81% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 45.91 vs. SNPHY: 28.10 )
SNPHY' s 10-Year POCF Range
Min: 3.42   Max: 39.58
Current: 28.1

3.42
39.58
EV-to-EBIT 3.98
SNPHY's EV-to-EBIT is ranked higher than
99% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 43.18 vs. SNPHY: 3.98 )
SNPHY' s 10-Year EV-to-EBIT Range
Min: -0.7   Max: 25.1
Current: 3.98

-0.7
25.1
PEG 6.65
SNPHY's PEG is ranked higher than
86% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNPHY: 6.65 )
SNPHY' s 10-Year PEG Range
Min: 3.57   Max: 4.03
Current: 6.65

3.57
4.03
Current Ratio 3.23
SNPHY's Current Ratio is ranked higher than
80% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.13 vs. SNPHY: 3.23 )
SNPHY' s 10-Year Current Ratio Range
Min: 2.08   Max: 7.34
Current: 3.23

2.08
7.34
Quick Ratio 2.80
SNPHY's Quick Ratio is ranked higher than
82% of the 1100 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNPHY: 2.80 )
SNPHY' s 10-Year Quick Ratio Range
Min: 1.79   Max: 6.38
Current: 2.8

1.79
6.38
Days Inventory 127.40
SNPHY's Days Inventory is ranked higher than
73% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 148.81 vs. SNPHY: 127.40 )
SNPHY' s 10-Year Days Inventory Range
Min: 119.64   Max: 171.04
Current: 127.4

119.64
171.04

Dividend & Buy Back

vs
industry
vs
history
Dividend Yield 3.40
SNPHY's Dividend Yield is ranked higher than
95% of the 681 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.30 vs. SNPHY: 3.40 )
SNPHY' s 10-Year Dividend Yield Range
Min: 1.14   Max: 3.57
Current: 3.4

1.14
3.57
Dividend Payout 1.11
SNPHY's Dividend Payout is ranked higher than
78% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 0.00 vs. SNPHY: 1.11 )
SNPHY' s 10-Year Dividend Payout Range
Min: 0.65   Max: 2.38
Current: 1.11

0.65
2.38
Dividend growth (3y) 3.60
SNPHY's Dividend growth (3y) is ranked higher than
71% of the 481 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 6.80 vs. SNPHY: 3.60 )
SNPHY' s 10-Year Dividend growth (3y) Range
Min: 0   Max: 3.6
Current: 3.6

0
3.6
Yield on cost (5-Year) 3.40
SNPHY's Yield on cost (5-Year) is ranked higher than
89% of the 688 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.53 vs. SNPHY: 3.40 )
SNPHY' s 10-Year Yield on cost (5-Year) Range
Min: 1.14   Max: 3.57
Current: 3.4

1.14
3.57
Share Buyback Rate 1.10
SNPHY's Share Buyback Rate is ranked higher than
93% of the 770 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: -1.60 vs. SNPHY: 1.10 )
SNPHY' s 10-Year Share Buyback Rate Range
Min: 1.1   Max: -0.8
Current: 1.1

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 0.70
SNPHY's Price/Tangible Book is ranked higher than
96% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 7.30 vs. SNPHY: 0.70 )
SNPHY' s 10-Year Price/Tangible Book Range
Min: 1.68   Max: 2.98
Current: 0.7

1.68
2.98
Price/Median PS Value 1.60
SNPHY's Price/Median PS Value is ranked higher than
67% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 1.60 vs. SNPHY: 1.60 )
SNPHY' s 10-Year Price/Median PS Value Range
Min: 0.22   Max: 3.89
Current: 1.6

0.22
3.89
Price/Graham Number 0.50
SNPHY's Price/Graham Number is ranked higher than
99% of the 1267 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.40 vs. SNPHY: 0.50 )
SNPHY' s 10-Year Price/Graham Number Range
Min: 0.2   Max: 1.19
Current: 0.5

0.2
1.19
Earnings Yield (Greenblatt) 24.90
SNPHY's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1148 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 2.90 vs. SNPHY: 24.90 )
SNPHY' s 10-Year Earnings Yield (Greenblatt) Range
Min: 4   Max: 24.9
Current: 24.9

4
24.9
Forward Rate of Return (Yacktman) -12.01
SNPHY's Forward Rate of Return (Yacktman) is ranked higher than
57% of the 576 Companies
in the Global Drug Manufacturers - Major industry.

( Industry Median: 8.03 vs. SNPHY: -12.01 )
SNPHY' s 10-Year Forward Rate of Return (Yacktman) Range
Min: -31.9   Max: 26.7
Current: -12.01

-31.9
26.7

Analyst Estimate

Mar15
EPS($) 2.27
EPS without NRI($) 2.27

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Major
Compare: » details
Traded in other countries:SZD.Germany, 4536.Japan,
Santen Pharmaceutical Co Ltd.
» More Articles for SNPHY

Headlines

Articles On GuruFocus.com
No related article found.

More From Other Websites
No related articles found.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK